Welcome To ChemAnalyst
Etoricoxib prices in China fell sharply in July 2025 due to high inventories, increased supply after production restarts, and weak export demand amid global trade uncertainty. While domestic demand from pharmaceuticals remained steady, reduced international orders and intense competition pressured the market. Prices are expected to rise in early August as domestic demand recovers, trade sentiment improves, and full-capacity production supports gradual market stabilization.
Etoricoxib prices in the Chinese market saw a sharp decrease in July 2025, indicating a combination of weak market demand, high inventories and widespread market uncertainties. Supply levels rose sharply following resumption of production following the June shutdown of the plant piling more pressure on an already large stockpile. Adverse monsoon conditions and regional flooding left suppliers in rush to clear stocks, many of whom offered aggressive discounts to effect sales.
Even though a temporary shutdown of the plant was witnessed in Sichuan Yujian Pharmaceutical Co., Ltd. during the month, the market prices of Etoricoxib were not affected by this as there were very high volumes of stocks in the supply chain. The wider manufacturing industry also came across formidable winds, and the sector shrank the second time in three months as new export orders fell precipitously. Buyer sentiment was affected strongly by uncertainty in global trade, especially in pharmaceutical exports, producing a dampened global procurement activity.
Although China has long-term plans to upgrade its industries in the 2025 plan under the Made in China 2025 initiative, there has been an insignificant improvement in the market conditions of Etoricoxib in the short-term. Increases in the prices of raw materials exerted an upward impact on the prices of inputs, but with intense competition in the global market, sellers did not have much ground to transfer the costs to their buyers. There were no major bottlenecks in the supply chain as the USD/CNY rate was stable and smooth domestic logistics went well, however, this only reinforced the imbalance between high availability and weak demand, keeping Etoricoxib prices under sustained pressure.
From a demand perspective, July saw muted interest in Etoricoxib both domestically and internationally. While consumption from China’s core pharmaceutical and healthcare sectors remained steady, the contraction in overseas orders was more pronounced. Heightened trade tensions, especially following the imposition of higher U.S. import tariffs, discouraged international buyers, who chose to scale back purchasing and rely on existing inventories. This cautious approach further reduced the urgency for fresh procurement of Etoricoxib and contributed to an oversupplied market.
Export demand was notably weak for Etoricoxib, with overseas buyers in key regions such as North America, Europe, and parts of Asia slowing their purchasing cycles. At the same time, suppliers in China faced increased competition from other low-cost manufacturing hubs, intensifying the downward price trend. The combination of these factors created a challenging environment for Etoricoxib producers, who were forced to navigate both domestic stability and global market volatility.
Market analysts predict that Etoricoxib prices in China will rebound in the first half of August 2025. Presumably, the slow recovery of domestic demand and rising purchases by pharmaceutical manufacturers will encourage constant price growth. Moreover, a reduction of trade uncertainties is likely to restore the confidence of international buyers, which will support export demand. As factories are expected to run at full potential, the supply will continue to align and the Etoricoxib market is expected to become viable to a gradual and sustained price recovery.
We use cookies to deliver the best possible experience on our website. To learn more, visit our Privacy Policy. By continuing to use this site or by closing this box, you consent to our use of cookies. More info.